| Expression pattern: |
UP |
| Associated gene: |
FUS, FOXR2 |
| Associated microRNA: |
- |
| Biological function: |
Promotes paclitaxel chemoresistance, cell viability, proliferation and tumor growth; inhibits PTX-induced cytotoxicity and apoptosis; supports FOXR2 expression and mRNA stability. |
| Molecular mechanism: |
circANKRD17 interacts with the RNA-binding protein FUS and recruits it to FOXR2, enhancing FOXR2 mRNA stability and increasing FOXR2 expression, thereby promoting PTX chemoresistance. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); cell cycle (other); mRNA stability (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Actinomycin D / DRB Stability Assay; RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis; Transfection; CCK8; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
High circANKRD17 expression was correlated with PTX resistance and poor prognosis; patients with high expression displayed shorter overall survival. |
| Description: |
circANKRD17 is up-regulated in ovarian cancer, especially PTX-resistant tissues and cell lines, and high expression is associated with poorer overall survival. It promotes paclitaxel chemoresistance and tumor growth by interacting with the RNA-binding protein FUS to stabilize FOXR2 mRNA and increase FOXR2 expression. |
| Confidence score: |
0.8743 |